


AUSSCHREIBUNG ABSCHLUSSARBEIT: *VALUATION OF EARLY-STAGE DRUG CANDIDATES TAKING INTO ACCOUNT INVESTMENTS, RISK AND MARKET SIZES*



KEY FACTS ABOUT THE THESIS:

VALUATION OF EARLY-STAGE DRUG CANDIDATES TAKING INTO ACCOUNT INVESTMENTS, RISK AND MARKET SIZES

- This Thesis will be performed in collaboration with [InterAx Biotech AG](#), Switzerland, and should be conducted in coordination and exchange with a representative of the firm.
- Goal of this thesis is to research and define basic assumptions for drug discovery costs, risks and market sizes for given medical indications.
- The risk-adjusted net present value (rNPV)* should be calculated at different stages with previously acquired data and compared with other valuation methods.
- Prior knowledge of quantitative finance and a strong interest in the pharmaceutical industry are advantageous when choosing this topic.
- Please contact Prof. Dr. Carolin Bock briefly explaining your motivation with CV current Transcript of Records attached: bock@ent.tu-darmstadt.de

Reference: Stewart et al.: Putting a price on biotechnology. Nature Biotechnology, 2001